Bangalore Call Girls Hebbal Kempapura Number 7001035870 Meetin With Bangalor...
HPV, Cervical cancer prevention and screening
1. 8/8/2020
1
Human papillomavirus
in 2019:
An update on cervical
cancer
prevention & screening
guidelines
Prof Aboubakr Elnashar
Benha university hospital,
Egypt
ABOUBAKR ELNASHAR
8/8/2020
2
CONTENTS
I. HPV:
1. Types
2. Infection
3. How Infection Lead To Cancer
4. Risk Factors For Development Of Cancer
II. PREVENTION OF CERVICAL CANCER
I. PRIMARY PREVENTION: HPV VACCINATION
II.2NDRY PREVENTION: SCREENING & TREATMENT OF CIN
III.TERTIARY PREVENTION
ABOUBAKR ELNASHAR
2. 8/8/2020
3
CERVICAL CANCER
The 4th most frequent cancer in women with an
570 000 new cases in 2018
7.5% of all female cancer deaths.
311 000 deaths from cervical cancer every year
85% of these occur in less developed regions.
ABOUBAKR ELNASHAR
8/8/2020
4
CIN in Egypt
(Elnashar, 2019)
Aboubakr ElnasharABOUBAKR ELNASHAR
3. 8/8/2020
5
Cx ca in Egypt:
0.04%
(AbdelAll et al, 2007)
0.06% populations
[Feraly et al, 2010)
8th among the most common females' cancers
(National Cancer Institute registry for the years 2002- 2004)
Increasing incidence from 2002 to 2004
[Elattar, 2004)
Increase by 34.0% from 2013 to 2050
[Ebrahim et al, 2014)
Aboubakr ElnasharABOUBAKR ELNASHAR
8/8/2020
6
I. HPV
1. Types
1. Cancer causing types
Cervical cancer
The most common HPV-related disease.
Nearly all cases of cervical cancer can be
attributable to HPV infection.
Cancers of anus, vulva, vagina, penis, oropharynx
are preventable using similar primary prevention
strategies as those for cervical cancer.
ABOUBAKR ELNASHAR
4. 8/8/2020
7
Non-cancer causing types
Especially types 6, 11
Can cause
Genital warts
very common
highly infectious & affect sexual life.
Respiratory papillomatosis
Tumours grow in the air passages leading
from the nose& mouth into the lungs.
Very rarely result in death
ABOUBAKR ELNASHAR
8/8/2020
8
HPV and Anogenital Warts
• HPV 6 and 11 responsible
for >90% of anogenital
warts1
• Clinically apparent in ~1%
of sexually active US adult
population2
• Estimated lifetime risk of
developing genital warts
~10%3,4
1. Jansen KU, Shaw AR. Annu Rev Med. 2004;55:319–331. 2. Koutsky L. Am J Med. 1997;102:3–8. 3. Franco EL, Villa LL,
Richardson H, Rohan TE, Ferenczy A. In: Franco EL, Monsonego J, eds. Oxford, UK: Blackwell Science; 1997:14–22. 4. Tortolero-
Luna G. Hematol Oncol Clin North Am. 1999;13:245–257, x.
Images top left and top right: Reprinted with permission from
NZ DermNet (www.dermnetnz.org)
5. 8/8/2020
9
ABOUBAKR ELNASHAR
8/8/2020
10
2. HPV infections
The most common viral infection of reproductive tract.
Most sexually active women& men will be infected at some
point in their lives
Some may be repeatedly infected.
The peak time for acquiring infection (for both women& men):
shortly after becoming sexually active.
HPV is sexually transmitted
Penetrative sex is not required for transmission.
Skin-to-skin genital contact is a well-recognized mode of
transmission.
ABOUBAKR ELNASHAR
6. 8/8/2020
11
3. How HPV infection leads to cervical cancer
Most HPV infections
Clear up on their own within a few months
90% clear within 2 years.
Most pre-cancerous lesions resolve spontaneously
ABOUBAKR ELNASHAR
8/8/2020
12
Small proportion of infections
Certain types of HPV
Become ch & pre-cancerous lesions progress to
invasive cervical cancer.
For cervical cancer to develop
Normal immunity: 15 to 20 y
Compromised immunity (HIV): 5 to 10 y
ABOUBAKR ELNASHAR
7. 8/8/2020
13
0–1 Year 0–5 Years 1–20 Years
Invasive
Cervical
Cancer
Cleared HPV Infection
1. Adapted from Pinto AP, Crum CP. Clin Obstet Gynecol. 2000;43:352–362.
CIN 1
Initial
HPV
Infection
Continuing
Infection
CIN
2/3
Natural History of HPV Infection and Potential
Progression to Cervical Cancer1
ABOUBAKR ELNASHAR
8/8/2020
14
Mechanisms of HPV Transmission and Acquisition
– Sexual contact
• Through sexual intercourse1
• Genital–genital, manual–genital, oral–genital2–4
• Genital HPV infection in virgins is rare, but may result
from nonpenetrative sexual contact.2
• Proper condom use may help reduce the risk, but is not
fully protective against infection.5
– Nonsexual routes
• Mother to newborn (vertical transmission)6
• Fomites (eg, undergarments, surgical gloves, biopsy
forceps)7,8
– Hypothesized but not well documented; would be rare
– Most infected individuals are unaware that they are
infected and may unknowingly spread the virus.9
1. Kjaer SK, Chackerian B, van den Brule AJ, et al. Cancer Epidemiol Biomarkers Prev. 2001;10:101–106. 2. Winer RL, Lee S-K, Hughes JP, Adam
DE, Kiviat NB, Koutsky LA. Am J Epidemiol. 2003;157:218–226. 3. Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM. Epidemiol Infect.
1995;115:169–176. 4. Herrero R, Castellsagué X, Pawlita M, et al. J Natl Cancer Inst. 2003;95:1772–1783. 5. Manhart LE, Koutsky LA. Sex
Transm Dis. 2002;29:725–735. 6. Smith EM, Ritchie JM, Yankowitz J, et al. Sex Transm Dis. 2004;31:57–62. 7. Ferenczy A, Bergeron C, Richart
RM. Obstet Gynecol. 1989;74:950–954. 8. Roden RBS, Lowy DR, Schiller JT. J Infect Dis. 1997;176:1076–1079. 9. Anhang R, Goodman A, Goldie
SJ. CA Cancer J Clin. 2004;54:248–259.
ABOUBAKR ELNASHAR
9. 8/8/2020
17
4. Risk factors for HPV persistence & development
of cervical cancer
1. HPV type: its oncogenicity
2. Immune status
immunocompromised(HIV) more likely to
have persistent HPV infections
rapid progression to pre-cancer and cancer
3. Coinfection with other STD
herpes simplex, chlamydia, gonorrhoea
4. Young age at first birth
5. Tobacco smoking ABOUBAKR ELNASHAR
8/8/2020
18
III. PREVENTION OF CERVICAL CANCER
In developed countries
Programmes are in place which enable
Girls to be vaccinated against HPV
Women to get screened regularly.
Screening allows pre-cancerous lesions to be
identified at stages when they can easily be
treated.
Early treatment prevents up to 80% of cervical
cancers in these countries.
ABOUBAKR ELNASHAR
10. 8/8/2020
19
In developing countries
Access to preventative measures: limited
Cervical cancer is often not identified until it
has further advanced &symptoms develop
Access to treatment of such late-stages
(surgery, radiotherapy, chemotherapy): very
limited: higher rate of death
ABOUBAKR ELNASHAR
8/8/2020
20
Cervical Cancer Prevention & Control
Comprehensive Approach: WHO, 2018
Interventions across the life course.
Multidisciplinary
Community education, social mobilization
Vaccination
Screening
Treatment & palliative care.
ABOUBAKR ELNASHAR
11. 8/8/2020
21
ABOUBAKR ELNASHAR
8/8/2020
22
PRIMARY PREVENTION: (WHO, 2018)
1. HPV vaccination of girls aged 9-14 years, before they
become sexually active.
2. Other recommended preventive interventions
Education:
safe sexual practices
delayed start of sexual activity
Promotion & provision of condoms for those
already engaged in sexual activity
Warnings about tobacco use
Male circumcision.ABOUBAKR ELNASHAR
12. 8/8/2020
23
HPV VACCINATION
TYPES
FDA has approved 3 HPV vaccines
WHO considers the 3 vaccines equally protective
against cervical cancer.
ABOUBAKR ELNASHAR
8/8/2020
24
ABOUBAKR ELNASHAR
13. 8/8/2020
25
The bivalent vaccine (Cervarix)
Targeted HPV 16 & 18 only
discontinued in USA in 2016
ABOUBAKR ELNASHAR
8/8/2020
26
The quadrivalent HPV vaccine (Gardasil)
targeted HPV 16 and 18 as well as 6 and 11,
which cause most cases of genital warts;
The last available doses in USA expired in 2017
it has been replaced by Gardasil 9.
ABOUBAKR ELNASHAR
14. 8/8/2020
27
Gardasil 9
Targets HPV types
6, 11, 16, and18 along with 31, 33, 45, 52, 58
These cause
90% of cervical cancer cases
Most cases of genital warts
The most effective vaccine available
The only HPV vaccine available in USA
ABOUBAKR ELNASHAR
8/8/2020
28
SCHEDULE
Changes in vaccination schedule
Patients younger than 15 need only 2 rather than
3 doses
(The Advisory Committee on Immunization Practices (ACIP, 2016)
Vaccine can be used in men& women up to age
45.
(FDA,2018)
ABOUBAKR ELNASHAR
15. 8/8/2020
29
WHO: vaccination for girls between 9 &14 y:?
when most have not started sexual activity.
{most cost-effective health measure against
cervical cancer
HPV vaccines work best if administered prior to
exposure to HPV}.
ABOUBAKR ELNASHAR
8/8/2020
30
EFFECTIVENESS
HPV vaccination
can prevent up to
70% of cases of cervical cancer due to HPV
90% of genital warts
(Thaxton L, Waxman, 2015).
The incidence of cervical cancer in USA dropped 29% among 15- to
24-year-olds from 2003–2006 when HPV vaccination first started to
2011–2014.
(Guo et al, 2018)
Cannot treat HPV infection or HPV-associated disease,
such as cancer.
Does not replace cervical cancer screening.ABOUBAKR ELNASHAR
16. 8/8/2020
31
CHALLENGES OF VACCINATION
Effective patient & family counseling is important.
The first HPV vaccine was approved in 2006
only 34.9% of US adolescents were vaccinated by 2015.
1. Providers
did not recommend it,
were unfamiliar with it, or
had concerns about its safety
(Thompson et al, 2017)
2. Some parents refused it.
The physician must address
any myths
Ensure that parents & patients understand that HPV vaccine is
safe & effective.
ABOUBAKR ELNASHAR
8/8/2020
32
FACTS ABOUT HPV VACCINE
(American Cancer Society, 2018).
Safe
No bad side effects
Does not cause fertility problems
Does not contain harmful ingredients
Not opening the door to having sex
For both males & females
Works & can help prevent cervical cancer
Last a long time, may be forever
ABOUBAKR ELNASHAR
17. 8/8/2020
33
SECONDARY PREVENTION:
CERVICAL CANCER SCREENING& TT
Screening:
Definition
Systematic application of a test in
asymptomatic person
to identify pre clinical lesions.
Types :
Selective: Screening high risk groups
Mass: Screening all population
ABOUBAKR ELNASHAR
8/8/2020
34
Screening:
has to be linked to access to management of
positive screening tests
Without proper management is not ethical.
Since the introduction of Pap test, US cervical
cancer incidence decreased by 60%.
(National Cancer Institute, 2019)
Because almost all cervical cancer is preventable
with proper screening, all women ages 21 to 65
should be screened.
ABOUBAKR ELNASHAR
18. 8/8/2020
35
I. WHO, 2018
There are 3 different types of screening tests
1. HPV testing for high-risk HPV types.
2. Visual inspection with Acetic Acid (VIA)
3. Conventional (Pap) test and
liquid-based cytology (LBC)
ABOUBAKR ELNASHAR
8/8/2020
36
Selection of screen depends on existing resources
rather than differences in efficacy
If resources permit
1. HPV test or HPV test followed by VIA
suggested for screening
2. HPV test (or HPV test followed by VIA)
suggested over screening strategy of
1. VIA
2. Cytology followed by colposcopy
3. HPV test followed by colposcopy
ABOUBAKR ELNASHAR
19. 8/8/2020
37
In resource-constrained settings
VIA
suggested over screening strategy of HPV test
recommended over screening strategy of
cytology followed by colposcopy
Any strategy using colposcopy for follow-up of positive screening test may
lead to treatment if colposcopy positive or biopsy to guide treatment
if high quality screening program already in place, protocol of screening with
cytology or HPV test followed by colposcopy may continue to be used
ABOUBAKR ELNASHAR
8/8/2020
38
Treatment strategies (for positive screening)
Cryotherapy is preferred TT in any screen& treat
strategy if all of the following
Entire lesion is visible
SCJ is visible
Lesion is not > 75% of ectocervix
LEEP/LLETZ is preferred option if cryotherapy is
contraindicated
Using VIA to determine treatment eligibility (cryotherapy vs. LEEP)
recommended for all women with positive screening, this is different
than using VIA as screening test
ABOUBAKR ELNASHAR
20. 8/8/2020
39
Cold knife conization should not be used in screen&
treat strategy (WHO Strong Recommendation, Very
low-quality evidence) due to risk of major bleeding and
premature delivery
ABOUBAKR ELNASHAR
8/8/2020
40
Follow -up intervals
if HPV negative, rescreen after ≥ 5 years (or within 3
years if HIV positive or unknown HIV status in area with high endemic
HIV infection)
if HPV positive&VIA negative, rescreen after 1 year
if HPV positive and colposcopy negative (or biopsy
shows CIN 1 or less), rescreen within 3 years
if VIA negative, rescreen every 3-5 years (or within 3
years if HIV positive or unknown HIV status in area with high endemic
HIV infection)
ABOUBAKR ELNASHAR
21. 8/8/2020
41
if cytology normal, rescreen every 3-5 years (or within 3
years if HIV positive or unknown HIV status in area with high endemic HIV
infection)
If cytology ASCUS or greater and colposcopy
negative (or biopsy shows CIN 1 or less), rescreen
within 3 years
If abnormality treated with cryotherapy or LEEP,
follow up posttreatment at 1 year regardless of
strategy, treat any lesion suspicious for cancer
(WHO, 2013)
ABOUBAKR ELNASHAR
8/8/2020
42
ABOUBAKR ELNASHAR
22. 8/8/2020
43
II. ASCCP2012, USPSTF2018; ACOG 2019
3 options available for cervical cancer screening:
1. Pap-only test
2. Pap-HPV cotest
3. High -risk HPV only test
The latter 2 options detect high-risk HPV
genotypes.
ABOUBAKR ELNASHAR
8/8/2020
44
ABOUBAKR ELNASHAR
23. 8/8/2020
45
Pap-only testing
performed every 3 y
Pap-HPV cotesting
Performed every 5 y in women older than 30 with
past normal screening.
Until 2018, all 3 organizations recommended
cotesting as the preferred screening algorithm for
women ages 30 to 65.
Patients with a history of abnormal test results
require more frequent testing as recommended by
the ASCCP, 2012
ABOUBAKR ELNASHAR
8/8/2020
46
The high-risk HPV-only test
utilizes real-time PCR to detect
HPV 16,
HPV 18, and
12 other HPV genotypes.
ABOUBAKR ELNASHAR
24. 8/8/2020
47
ASCCP, ACOG
ABOUBAKR ELNASHAR
8/8/2020
48
Is there a best screening protocol?
Both cotesting & high-risk HPV testing
offer similar cancer detection rates:
each prevents 1 additional cancer per 1,000 women screened as
opposed to Pap-only testing.
(USPSTF; 2018)
more likely to require additional colposcopies for
follow-up than Pap-only screening
(1,630 colposcopies required for each cancer prevented with high-risk HPV
alone, 1,635 with cotesting).
ABOUBAKR ELNASHAR
25. 8/8/2020
49
High-risk HPV screening
offer better detection of cervical adenocarcinoma
(which has a worse prognosis than the more common squamous cell
carcinoma type).
should be repeated every 5 years if normal (as
opposed to every 3 years as recommended by
(ACOG, 2019 and ASCCP, 2012).
All 3 cervical cancer screening methods
provide highly effective cancer prevention: choose
the strategy that best fits practice.
ABOUBAKR ELNASHAR
8/8/2020
50
1 round of high-risk HPV-only screening for women
older than 25 was more sensitive than Pap-only or
cotesting for stage 3 CIN or more severe disease
(after 3 years of follow-up).
(Wright et al, 2015, Addressing the Need for Advanced HPV Diagnostics
(ATHENA)
ABOUBAKR ELNASHAR
26. 8/8/2020
51
The most critical aspect of screening is getting all
women screened, no matter which method is used.
Screening intervals are intended for patients without
symptoms.
Those who have new concerns such as bleeding
should have a diagnostic Pap done to evaluate their
symptoms.
ABOUBAKR ELNASHAR
8/8/2020
52
HPV TESTS
High -risk HPV only tests
Only 2 tests are approved by the FDA as stand-alone cervical cancer
screening tests
Roche Cobas HPV test approved in 2014
Becton Dickinson Onclarity HPV assay
approved in 2018.
Other HPV tests that are used in a cotesting strategy
should not be used for high-risk HPV-only testing
because their performance characteristics may differ.
ABOUBAKR ELNASHAR
28. 8/8/2020
55
ABOUBAKR ELNASHAR
8/8/2020
56
You can get this lecture and 450 lectures from:
1.My scientific page on Face book: Aboubakr
Elnashar Lectures.
https://www.facebook.com/groups/2277448840913
51/
2.Slide share web site
3.elnashar53@hotmail.com
4.My clinic: Elthwara St. Mansura
ABOUBAKR ELNASHAR